$RYTM
RHYTHM PHARMACEUTICALS, INC.

2021 Q1 Form 10-Q Financial Statement

#000155837021005475 Filed on May 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $35.00K $0.00
YoY Change
Cost Of Revenue $4.000K
YoY Change
Gross Profit $31.00K
YoY Change
Gross Profit Margin 88.57%
Selling, General & Admin $14.52M $12.80M
YoY Change 13.46% 64.9%
% of Gross Profit 46832.26%
Research & Development $19.91M $22.50M
YoY Change -11.52% -1.12%
% of Gross Profit 64229.03%
Depreciation & Amortization $201.0K $167.0K
YoY Change 20.36% -33.2%
% of Gross Profit 648.39%
Operating Expenses $34.43M $35.30M
YoY Change -2.47% 15.66%
Operating Profit -$34.40M -$35.30M
YoY Change -2.56%
Interest Expense $150.0K $1.140M
YoY Change -86.84% -26.45%
% of Operating Profit
Other Income/Expense, Net $100.2M $1.136M
YoY Change 8716.37%
Pretax Income $65.76M -$34.16M
YoY Change -292.47% 17.93%
Income Tax $22.01M
% Of Pretax Income 33.47%
Net Earnings $43.75M -$34.16M
YoY Change -228.06% 17.91%
Net Earnings / Revenue 125000.0%
Basic Earnings Per Share $0.92 -$0.78
Diluted Earnings Per Share $0.90 -$0.78
COMMON SHARES
Basic Shares Outstanding 47.64M 44.05M
Diluted Shares Outstanding 48.50M 44.05M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $404.8M $257.4M
YoY Change 57.26% 16.21%
Cash & Equivalents $87.27M $56.18M
Short-Term Investments $317.5M $201.6M
Other Short-Term Assets $7.400M $10.40M
YoY Change -28.85% 20.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $412.1M $267.9M
YoY Change 53.84% 16.38%
LONG-TERM ASSETS
Property, Plant & Equipment $3.006M $5.500M
YoY Change -45.35% -6.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $400.0K
YoY Change -25.0% 0.0%
Total Long-Term Assets $10.08M $5.900M
YoY Change 70.76% -6.35%
TOTAL ASSETS
Total Short-Term Assets $412.1M $267.9M
Total Long-Term Assets $10.08M $5.900M
Total Assets $422.2M $273.8M
YoY Change 54.2% 15.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.147M $5.900M
YoY Change 55.03% 47.5%
Accrued Expenses $7.150M $11.80M
YoY Change -39.41% 37.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.85M $17.70M
YoY Change -4.8% 40.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.400M $3.000M
YoY Change -20.0% -11.76%
Total Long-Term Liabilities $2.400M $3.000M
YoY Change -20.0% -11.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.85M $17.70M
Total Long-Term Liabilities $2.400M $3.000M
Total Liabilities $41.26M $20.70M
YoY Change 99.33% 29.38%
SHAREHOLDERS EQUITY
Retained Earnings -$415.6M
YoY Change
Common Stock $50.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $380.9M $253.1M
YoY Change
Total Liabilities & Shareholders Equity $422.2M $273.8M
YoY Change 54.2% 15.77%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $43.75M -$34.16M
YoY Change -228.06% 17.91%
Depreciation, Depletion And Amortization $201.0K $167.0K
YoY Change 20.36% -33.2%
Cash From Operating Activities -$33.53M -$36.10M
YoY Change -7.11% 15.04%
INVESTING ACTIVITIES
Capital Expenditures $12.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$145.7M $28.87M
YoY Change -604.68% 18.56%
Cash From Investing Activities -$145.7M $28.87M
YoY Change -604.67% 22.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $161.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 165.6M 707.0K
YoY Change 23320.79% 120.94%
NET CHANGE
Cash From Operating Activities -33.53M -36.10M
Cash From Investing Activities -145.7M 28.87M
Cash From Financing Activities 165.6M 707.0K
Net Change In Cash -13.66M -6.518M
YoY Change 109.54% -13.32%
FREE CASH FLOW
Cash From Operating Activities -$33.53M -$36.10M
Capital Expenditures $12.00K $0.00
Free Cash Flow -$33.54M -$36.10M
YoY Change -7.08% 18.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50201758
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44235903
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001649904
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38223
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
RHYTHM PHARMACEUTICALS, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2159271
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
222 Berkeley Street
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
12th Floor
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2021Q1 dei City Area Code
CityAreaCode
857
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
264-4280
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
RYTM
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50206758
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87271000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100854000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
317479000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
71938000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7384000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8876000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
412134000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
181668000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3006000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3195000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1741000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1807000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5000000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
328000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
403000
CY2021Q1 us-gaap Assets
Assets
422209000
CY2020Q4 us-gaap Assets
Assets
187073000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9147000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4900000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7150000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12559000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
553000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
535000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16850000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17994000
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
22006000
CY2021Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2406000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2551000
CY2021Q1 us-gaap Liabilities
Liabilities
41262000
CY2020Q4 us-gaap Liabilities
Liabilities
20545000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50201758
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44235903
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
50000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
796532000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
625762000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-415577000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-459327000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
380947000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166528000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
422209000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
187073000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
35000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19911000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22504000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14518000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12796000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
34433000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
35300000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34398000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35300000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
100000000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
154000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1136000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
100154000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1136000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
65756000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-34164000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22006000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
43750000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-34164000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.92
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.90
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47638565
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44049843
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48501697
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44049843
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
43750000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-34164000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-107000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
63000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
43643000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34101000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166528000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5191000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
388000
CY2021Q1 rytm Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
3466000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161731000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-107000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
43750000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
380947000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
281020000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5475000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
324000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
383000
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
63000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-34164000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
253101000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
43750000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-34164000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5191000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5475000
CY2021Q1 rytm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
100000000
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
22006000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
201000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
CY2021Q1 rytm Deferred Rent Expense
DeferredRentExpense
-61000
CY2020Q1 rytm Deferred Rent Expense
DeferredRentExpense
-56000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1651000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
847000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6269000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6673000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33531000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36098000
CY2021Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
297542000
CY2020Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
15370000
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
51842000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
44243000
CY2021Q1 rytm Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
100000000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145712000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28873000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161731000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3466000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
383000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
388000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
324000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165585000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
707000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13658000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6518000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101257000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62697000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87599000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56179000
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Rhythm Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (In thousands, except share and per share information)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rhythm Pharmaceuticals, Inc. (the “Company” or “we”) is a commercial-stage biopharmaceutical company focused on changing the paradigm for the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger or hyperphagia.  Our lead product candidate is IMCIVREE (setmelanotide), a potent melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic diseases of obesity. We believe IMCIVREE, for which we have exclusive worldwide rights, has the potential to restore dysfunctional MC4R signaling due to impaired MC4R pathway function. MC4R pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. IMCIVREE has been approved by the U.S. Food and Drug Administration, or FDA, for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin, or POMC, proprotein convertase subtilisin/kexin type 1, or PCSK1, or leptin receptor, or LEPR, deficiency confirmed by genetic testing. IMCIVREE is now commercially available.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a Delaware corporation organized in February 2013 under the name Rhythm Metabolic, Inc., and as of October 2015, under the name Rhythm Pharmaceuticals, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s continued development efforts are focused on obesity related to several single gene-related, or monogenic, MC4R pathway deficiencies: Bardet-Biedl syndrome, or BBS; Alström syndrome; HET obesity due to a genetic variant in one of the two alleles of the POMC, PCSK1 or LEPR gene, or HETs; obesity due to steroid receptor coactivator 1, or SRC1, deficiency; and obesity due to SH2B adapter protein 1, or SH2B1, deficiency; MC4R deficiency obesity and Smith-Magenis syndrome, as well as additional diseases as part of investigator-initiated protocols. Currently, there are no effective or approved treatments for these MC4R pathway-related diseases. The Company believes that the MC4R pathway is a compelling target for treating these genetic diseases because of its critical role in regulating appetite and weight by promoting satiety and weight control, and that peptide therapeutics are uniquely suited for activating this target. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"> <span style="background-color:#ffffff;">The Company is subject to risks and uncertainties common to commercial-stage companies in the biotechnology industry, including but not limited to risks associated with the commercialization of approved products, completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Commercialization of approved products will require significant resources and in order to market IMCIVREE, the Company must continue to build its sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has incurred operating losses and negative cash flows from operations since inception.  As of March 31, 2021, the Company had an accumulated deficit of $415,577.  The Company has primarily funded these losses through the proceeds from the sales of common and preferred stock, asset sales as well as capital contributions received from the former parent company, Rhythm Holdings LLC. To date, the Company has minimal product revenue and management expects operating losses to continue for the foreseeable future. The Company has devoted substantially all of its resources to its drug development efforts, comprising of research and development, manufacturing, conducting clinical trials for its product candidates, protecting its intellectual property, pre-commercialization activities and general and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Company completed the sale of a Rare Pediatric Disease Priority Review Voucher, or PRV, that it received in connection with the approval of IMCIVREE for $100,000. As the PRV did not have a carrying value, the gain recognized within Other income (loss) was equal to the gross proceeds received, with costs related to the sale of the voucher recorded within selling, general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At March 31, 2021, the Company had $404,750 of cash and cash equivalents and short-term investments on hand.  In the future, the Company will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, product sales and funded research and development programs to maintain the Company's operations and meet the Company's obligations. There is no guarantee that additional equity or other financings will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back, terminate its operations or seek to merge with or be acquired by another company. Management believes that the Company's existing cash resources will be sufficient to fund the Company's operations into at least the second half of 2023.</p>
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-415577000
CY2021Q1 rytm Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
100000000
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
404750000
CY2020Q1 rytm Unrealized Holding Gain Loss Available For Sale Securities Reclassified From Additional Paid In Capital To Accumulated Other Comprehensive Income Loss
UnrealizedHoldingGainLossAvailableForSaleSecuritiesReclassifiedFromAdditionalPaidInCapitalToAccumulatedOtherComprehensiveIncomeLoss
63000000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates relied upon in preparing these financial statements include accruals related to research and development expenses, assumptions used to record stock-based compensation expense and the valuation allowance on the Company's deferred tax assets.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Changes in estimates are recorded in the period in which they become known.  Actual results could differ materially from those estimates.</p>
CY2021Q1 rytm Number Of Federally Insured Financial Institutions
NumberOfFederallyInsuredFinancialInstitutions
2
CY2021Q1 rytm Number Of Federally Insured Financial Institutions
NumberOfFederallyInsuredFinancialInstitutions
2
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q1 rytm Revenue Performance Obligation Payment Terms
RevenuePerformanceObligationPaymentTerms
P45D
CY2021Q1 rytm Accounts Receivable Terms
AccountsReceivableTerms
P45D
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
648000
CY2021Q1 rytm Accrued Payroll Related Expense Current
AccruedPayrollRelatedExpenseCurrent
2073000
CY2020Q4 rytm Accrued Payroll Related Expense Current
AccruedPayrollRelatedExpenseCurrent
5916000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3739534
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4177009
CY2021Q1 rytm Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
3532000
CY2020Q4 rytm Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5815000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1316000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
180000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7150000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12559000
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
404750000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
172792000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
317538000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
60000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
317479000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71895000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
43000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
71938000
CY2021Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y3M18D
CY2021Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P6Y
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
603000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
818000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
834000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
851000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
502000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3608000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
649000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2959000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5000000.0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22006000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000
CY2021Q1 us-gaap Share Price
SharePrice
30.00
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161731000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
2811000

Files In Submission

Name View Source Status
0001558370-21-005475-index-headers.html Edgar Link pending
0001558370-21-005475-index.html Edgar Link pending
0001558370-21-005475.txt Edgar Link pending
0001558370-21-005475-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rytm-20210331.xsd Edgar Link pending
rytm-20210331x10q.htm Edgar Link pending
rytm-20210331x10q_htm.xml Edgar Link completed
rytm-20210331xex31d1.htm Edgar Link pending
rytm-20210331xex31d2.htm Edgar Link pending
rytm-20210331xex32d1.htm Edgar Link pending
rytm-20210331xex32d2.htm Edgar Link pending
rytm-20210331_cal.xml Edgar Link unprocessable
rytm-20210331_def.xml Edgar Link unprocessable
rytm-20210331_lab.xml Edgar Link unprocessable
rytm-20210331_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending